Kanamasa K, Kimura A, Miyataka M, Takenaka T, Ishikawa K
The First Department of Medicine, Kinki University School of Medicine, Osakasayama, Osaka, Japan.
Cancer. 1999 Mar 15;85(6):1369-74. doi: 10.1002/(sici)1097-0142(19990315)85:6<1369::aid-cncr21>3.0.co;2-5.
Recent reports suggest a possible link between nifedipine (but not diltiazem) and an increased risk of cancer in patients being treated with calcium antagonists.
A total of 1054 postmyocardial infarction patients were divided randomly into those being treated with calcium antagonists (n = 566 [nifedipine, 425 patients and diltiazem, 141 patients]) and controls (no calcium antagonist; n = 488). The patients were followed for 26.3 months, and the incidences of cardiac events as well as cancer were compared among the 3 groups.
Thirteen patients (2.7%) in the control group developed cancer, whereas 15 patients in the nifedipine group (3.5%; odds ratio, 1.34; 95% confidence interval [95% CI], 0.63-2.85) and 3 patients in the diltiazem group (2.1%; odds ratio, 0.89; 95% CI, 0.27-2.93) developed cancer.
Diltiazem appears to present no increased risk of cancer. The incidence of cancer was slightly higher in the patients receiving nifedipine than in those not being treated with a calcium antagonist, which is consistent with earlier reports; however, this increase was not statistically significant.
最近的报告表明，硝苯地平（而非地尔硫䓬）与接受钙拮抗剂治疗的患者患癌风险增加之间可能存在联系。
总共1054例心肌梗死后患者被随机分为接受钙拮抗剂治疗的患者（n = 566 [硝苯地平，425例患者；地尔硫䓬，141例患者]）和对照组（未使用钙拮抗剂；n = 488）。对患者进行了26.3个月的随访，并比较了三组中心脏事件和癌症的发生率。
对照组中有13例患者（2.7%）患癌，而硝苯地平组中有15例患者（3.5%；比值比，1.34；95%置信区间[95%CI]，0.63 - 2.85），地尔硫䓬组中有3例患者（2.1%；比值比，0.89；95%CI，0.27 - 2.93）患癌。
地尔硫䓬似乎不会增加患癌风险。接受硝苯地平治疗的患者癌症发生率略高于未接受钙拮抗剂治疗的患者，这与早期报告一致；然而，这种增加在统计学上并不显著。
